BK7508 Pharmaceutical Companies
Closed 01-27 16:00:00 AEDT
677.78
+10.89
+1.63%
High682.74Low671.78Vol47.14M
Open671.78D1 Closing666.89Amplitude1.64%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O159.38MT/O Rate--Tradable Shares0.00
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting
MT Newswires Live  ·  10:38
Mesoblast Says 84% Of Patients Completed 28-Day Ryoncil Treatment Regimen In 'Real-World' Clinical Setting
BRIEF-Monash IVF Group Says CFO Malik Jainudeen Resigns
Reuters  ·  09:48
BRIEF-Monash IVF Group Says CFO Malik Jainudeen Resigns
BRIEF-Anteotech Reports Capital Raise Of A$3.5 Million At A$0.0155 Per Share
Reuters  ·  09:15
BRIEF-Anteotech Reports Capital Raise Of A$3.5 Million At A$0.0155 Per Share
BUZZ-Australia's Anteotech falls to one-month low on discounted placement
Reuters  ·  09:04
BUZZ-Australia's Anteotech falls to one-month low on discounted placement
Monash IVF Group Ltd - Announces Resignation of CFO Malik Jainudeen
THOMSON REUTERS  ·  07:58
Monash IVF Group Ltd - Announces Resignation of CFO Malik Jainudeen
BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
Reuters  ·  07:48
BRIEF-Mesoblast Says Ryoncil Shows 84% Survival Rate In Children With Sr-Agvhd
Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd
THOMSON REUTERS  ·  07:47
Mesoblast Ltd - Ryoncil Shows 84% Survival Rate in Children With SR-Agvhd
Mesoblast Reports 84% Survival in Children Using Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease
Reuters  ·  07:45
Mesoblast Reports 84% Survival in Children Using Ryoncil for Steroid-Refractory Acute Graft-Versus-Host Disease
The Bull Case For Carlisle Companies (CSL) Could Change Following Its Vision 2030 Acquisition Drive – Learn Why
Simply Wall St.  ·  01-26 19:16
The Bull Case For Carlisle Companies (CSL) Could Change Following Its Vision 2030 Acquisition Drive – Learn Why
Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference
Reuters  ·  01-26 14:51
Immuron Limited Publishes Transcript of CEO Presentation at Emerging Growth Conference
ASX Penny Stocks To Watch In January 2026
Simply Wall St.  ·  01-26 03:02
ASX Penny Stocks To Watch In January 2026
Coinbase CEO Reacts as Solana Integration Gets 100% Complete
utoday  ·  01-24
Coinbase CEO Reacts as Solana Integration Gets 100% Complete
The 11% return this week takes Bioxyne's (ASX:BXN) shareholders five-year gains to 215%
Simply Wall St.  ·  01-23
The 11% return this week takes Bioxyne's (ASX:BXN) shareholders five-year gains to 215%
Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target
Reuters  ·  01-22
Emerging Growth Research Maintains Buy-Extended Rating on Immuron Limited With $3.50 Price Target
Mesoblast (ASX:MSB) Is Down 6.4% After Encouraging FDA Feedback On Back Pain Cell Therapy Data – Has The Bull Case Changed?
Simply Wall St.  ·  01-22
Mesoblast (ASX:MSB) Is Down 6.4% After Encouraging FDA Feedback On Back Pain Cell Therapy Data – Has The Bull Case Changed?
Botanix Pharmaceuticals Hosts Quarterly Update Webinar
Reuters  ·  01-22
Botanix Pharmaceuticals Hosts Quarterly Update Webinar
Shenzhen CSL Vacuum Science and Technology Prices IPO, Seeks Up to 1.56 Billion Yuan in Proceeds
MT Newswires Live  ·  01-22
Shenzhen CSL Vacuum Science and Technology Prices IPO, Seeks Up to 1.56 Billion Yuan in Proceeds
BRIEF-Anteotech Requests Trading Halt Pending Material Capital Raising
Reuters  ·  01-22
BRIEF-Anteotech Requests Trading Halt Pending Material Capital Raising
BRIEF-Australian Government Takeovers Panel Made Orders For Cosette
Reuters  ·  01-21
BRIEF-Australian Government Takeovers Panel Made Orders For Cosette
ACRES Commercial Realty to Issue $879.5 Million in Debt Notes
MT Newswires Live  ·  01-21
ACRES Commercial Realty to Issue $879.5 Million in Debt Notes

Introduction

Company Name.
BK7508
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--